[[ type === 'moc' ? 'MARKET ON CLOSE' : 'FREE WEBINAR' ]]
[[ timeLabel ]] WATCH LIVE:
Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Madrigal Pharmaceuticals Inc (MDGL)

Madrigal Pharmaceuticals Inc (MDGL)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]] ([[ financialData.relativeStrengthDirection14d ]]) ([[ financialData.highPercent1y ]]) ([[ financialData.lowPercent1y ]])
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 11,906,416
  • Shares Outstanding, K 23,104
  • Annual Sales, $ 958,400 K
  • Annual Income, $ -288,280 K
  • EBIT $ -323 M
  • EBITDA $ -316 M
  • 60-Month Beta -1.01
  • Price/Sales 12.30
  • Price/Cash Flow N/A
  • Price/Book 22.51

Options Overview Details

View History
  • Implied Volatility 41.79% (-0.94%)
  • Historical Volatility 48.89%
  • IV Percentile 3%
  • IV Rank 14.26%
  • IV High 73.99% on 11/03/25
  • IV Low 36.43% on 05/06/26
  • Expected Move (DTE 10) 13.60 (2.61%)
  • Put/Call Vol Ratio 0.13
  • Today's Volume 9
  • Volume Avg (30-Day) 323
  • Put/Call OI Ratio 0.57
  • Today's Open Interest 13,662
  • Open Int (30-Day) 13,382
  • Expected Range 506.81 to 534.01

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 19 analysts offering recommendations.
Earnings Estimates - Current Qtr 09/30/26
See More
  • Average Estimate $-1.00
  • Number of Estimates 6
  • High Estimate $-0.10
  • Low Estimate $-2.00
  • Prior Year $-5.08
  • Growth Rate Est. (year over year) +80.31%

Price Performance

See More
Period Period Low Period High Performance
1-Month
447.01 +16.18%
on 07/30/26
566.18 -8.27%
on 07/27/26
-17.35 (-3.23%)
since 07/10/26
3-Month
445.20 +16.66%
on 06/03/26
569.44 -8.80%
on 07/09/26
+22.32 (+4.49%)
since 05/11/26
52-Week
348.88 +48.86%
on 08/12/25
615.00 -15.55%
on 12/24/25
+169.85 (+48.60%)
since 08/11/25

Most Recent Stories

More News
Madrigal Pharmaceuticals Announces Grants of Inducement Awards under Nasdaq Listing Rule 5635(c)(4)

CONSHOHOCKEN, Pa., Aug. 06, 2026 (GLOBE NEWSWIRE) -- Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL), a biopharmaceutical company focused on delivering novel therapeutics for metabolic dysfunction-associated...

MDGL : 530.68 (+2.98%)
Madrigal Pharmaceuticals to Participate in the Canaccord Genuity 45th Annual Growth Conference

CONSHOHOCKEN, Pa., Aug. 06, 2026 (GLOBE NEWSWIRE) -- Madrigal Pharmaceuticals, Inc. (Nasdaq: MDGL) announced today that the company will participate in the Canaccord Genuity 46 th Annual Growth Conference...

MDGL : 530.68 (+2.98%)
Madrigal: Q2 Earnings Snapshot

Madrigal: Q2 Earnings Snapshot

MDGL : 530.68 (+2.98%)
Madrigal Pharmaceuticals Reports Second-Quarter 2026 Financial Results and Provides Corporate Updates

Second-quarter 2026 Rezdiffra ® (resmetirom) net sales of $364.3 million, representing year-over-year growth of 71% As of June 30, 2026, more than 49,000 patients on Rezdiffra, more...

MDGL : 530.68 (+2.98%)
Madrigal's Rezdiffra Revenue Momentum May Already Be Reflecting a Best-Case Scenario That Hasn't Arrived

Barchart Research What to Expect from MDGL Earnings MDGL Generated July 29, 2026 Current Price $546.88 EPS Estimate $$-2.55 Consensus Rating Strong Buy Average Move 10.51% Madrigal's Rezdiffra Revenue...

MDGL : 530.68 (+2.98%)
Madrigal Pharmaceuticals Announces Grants of Inducement Awards under Nasdaq Listing Rule 5635(c)(4)

CONSHOHOCKEN, Pa., July 21, 2026 (GLOBE NEWSWIRE) -- Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL), a biopharmaceutical company focused on delivering novel therapeutics for metabolic dysfunction-associated...

MDGL : 530.68 (+2.98%)
Madrigal Pharmaceuticals to Release Second-Quarter 2026 Financial Results and Host Webcast on July 30, 2026

CONSHOHOCKEN, Pa., July 16, 2026 (GLOBE NEWSWIRE) -- Madrigal Pharmaceuticals, Inc. (Nasdaq: MDGL) announced today that it will release its second-quarter 2026 financial results on Thursday, July 30,...

MDGL : 530.68 (+2.98%)
Madrigal Pharmaceuticals Announces Three New Resmetirom Patents, Strengthening IP Portfolio

Received two new U.S. Rezdiffra ® (resmetirom) patents in F2/F3; both patents will be listed in the FDA’s Orange Book Received new U.S. resmetirom patent directed to a method of administering...

MDGL : 530.68 (+2.98%)
Madrigal Pharmaceuticals Announces Grants of Inducement Awards under Nasdaq Listing Rule 5635(c)(4)

CONSHOHOCKEN, Pa., July 06, 2026 (GLOBE NEWSWIRE) -- Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL), a biopharmaceutical company focused on delivering novel therapeutics for metabolic dysfunction-associated...

MDGL : 530.68 (+2.98%)
Madrigal Pharmaceuticals Announces Grants of Inducement Awards under Nasdaq Listing Rule 5635(c)(4)

CONSHOHOCKEN, Pa., June 22, 2026 (GLOBE NEWSWIRE) -- Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL), a biopharmaceutical company focused on delivering novel therapeutics for metabolic dysfunction-associated...

MDGL : 530.68 (+2.98%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 72% Buy with a Average short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

See More Share

Business Summary

Madrigal Pharmaceuticals, Inc. is engaged in developing small-molecule drugs addressing cardiovascular and metabolic diseases. Its products pipeline include MGL-3196, an orally administered liver-directed thyroid hormone receptor-' agonist that is used for the treatment of NASH, dyslipidemia/hypercholesterolemia...

See More

Key Turning Points

3rd Resistance Point 537.75
2nd Resistance Point 527.61
1st Resistance Point 521.48
Last Price 530.68
1st Support Level 505.21
2nd Support Level 495.07
3rd Support Level 488.94

See More

52-Week High 615.00
Last Price 530.68
Fibonacci 61.8% 513.34
Fibonacci 50% 481.94
Fibonacci 38.2% 450.54
52-Week Low 348.88

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.